# 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

> **NCT00075608** · PHASE2 · TERMINATED · sponsor: **Boston Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** melphalan
- **PROCEDURE:** autologous stem cell transplantation
- **PROCEDURE:** stem cell infusion

## Key facts

- **NCT ID:** NCT00075608
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075608, "2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00075608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*